We describe an homogeneous luminescence immunoassay for "total" estrogens in enzymically hydrolyzed urine from nonpregnantwomen. The antiserum, raised against estriol-16,17-dihemisuccinateconjugatedto bovine serum albumin, specifically bound the C-19 steroids carrying the estrogencharacteristic phenolic group. 17/3-Estradiol conjugated with aminobutylethyl isoluminol was used to monitor the immunological reaction; this conjugate was stable for at least two sears. Because binding to the antiserum markedly enhances the light-producing efficiency of the tracer, no separation of bound and free antigen is necessary. Results (gf24 h) by this method (y) correlated well (r = 0.958) with those by a conventional fluorometnc (x) method (y = 2.51x -2.83). The sensitivity (detection limit) is 4 g/L and the precision compares well with that of commonly used RIA methods. The method appears suited to large numbers of samples, as in menstrual cycle monitoring. 30 to 300 ng/L, in the peripheral circulation of nonpregnant women. Moreover, because its concentration in plasma reportedly is subject to substantial circadian variation, several samples should be collected per day and analyzed if information is to be reliable (1).
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Measurement of total estrogens in urine is well related to the production of estrogens, but the fluorometric methods widely used for this are not easily performed and lack accuracy and specificity (2). Both gas-liquid chromatography (3) and liquid chromatography (4) have been used to provide probably the most nearly accurate measures of urinary estrogen content, but they are time-consuming and do not appear suitable for processing large numbers of samples. Both conventional RIA and nomsotopic luminescence immunoassay methods have been used to investigate some estrogen glucuronides in attempts to develop tests for the early prediction of ovulation (5) (6) (7) (8) , but none of the glucuromdes studied appeared unequivocally related to total estrogen production. Another nonisotopic assay, an enzymic measurement of urinary estrone plus estradiol (9) , is very simple and requires no special instrumentation, but it does not measure estriol, the principal metabolite of estrogens in urine.
To overcome some of the drawbacks of the above-mentioned methods, we developed an immunoassay for measure- ment of total urinary estrogens in which a chemiluminescent (CL) conjugate is the tracer and the antiserum specifically binds most of the urinary estrogens. 4 When the conjugate of steroid and CL marker is bound to specific antibody, the efficiency of the light-producing reaction is markedly enhanced.
The binding-and the consequent enhancement of light emission-is competitively inhibited by the addition of unconjugated steroid. The use of such a tracer allowed the development of an homogeneous immunoassay, which does not require any bound/free separation step.
Materials and Methods

Reagents.
All the steroids, "microperoxidase" (EC 1.11.1.7; MP-11, sodium salt, from equine heart cytochrome c), bovine serum albumin (BSA), and immunoglobulin The antiserum to "total" estrogens was raised in rabbits by using estriol-16,17-dihemisuccinate-BSA conjugate as the immunogen, as previously described (10).
Reagent solutions
for the CL reaction. The assay buffer was borate buffer, 0.1 molJL, pH 8.6, containing 9 g of NaCl, 80 mg of BSA, and 80 mg of human inimunoglobulin G per liter.
Microperoxidase (400 mg/L, 0.2 mniol/L), dissolved in Tris HC1 buffer (10 mmolfL, pH 7.4) and stored at 4#{176}C, was stable for at least four months. The working solution was a 20-fold dilution of this stock solution with assay buffer.
The starter solution was prepared by diluting the hydrogen peroxide solution 200-fold with doubly distilled water.
Preparation of the tracer. We used 6EN-(6-aminobutyl)-Nethyl]-amino-2,3-dihydrophthalazine-1,4-dione ("aminobutylethyl isoluminol," ABEl) as the CL label, prepared as described by Schroeder and Yeager (11). This product then was covalently linked to estradiol-1713-hemisuccinate to yield estradiol-17f3-hemisuccinate-ABEI (E2-ABEI, Figure  1) . The procedures for the synthesis and purification of the reaction product and for its characterization by ultraviolet spectrophotometry and mass spectrometry were as described elsewhere (12).
The conjugate, stored at -20 #{176}C as a 1 g/L solution in ethanol, was diluted with buffer at the time of assay. The stock solution is stable for at least two years. 
Instrumentation and light measurement.
We measured light emission with a luminometer (Picolite Model 6500; Packard Instrument Co.), using the automatic injection and integration modes of the instrument. To observe the shape of the curves generated in the light reaction, we connected the luminometer to a storage oscilloscope (Model 5111; Tektronix, Beaverton, OR) and a recorder (Model 2210; LKB, Bromma, Sweden). The luminometer displayed the arbitrary counts for the integrated 10-s interval after the injection of the starter reagent. Table 1 lists typical assay data for estrogens.
Results
Light yield of the E2-ABEI conjugate.
When various amounts of CL conjugate were treated with microperoxidase and hydrogen peroxide as described above, the light emission increased linearly with amount of tracer up to 5 pmol per tube. The lower limit of detection (background reading for reagent only ± 3 SD) was 5 fmol/tube.
Antiserum enhancement
effect. Figure 2 shows oscilloscope tracings of the light emission for oxidation of E2-ABEI conjugate (100 finol/tube) alone, in the presence of the specific antiserum, and in the presence of the antiserum plus 50 pg of cold 17/3-estradiol. Binding the conjugate to the antibody increases the emitted light by fivefold, but this effect is inhibited by the addition of the competitive unaltered steroid.
Antiserum titer determination.
To determine the working titer of the antiserum, we plotted the light enhancement produced by 100 fmol of the tracer in the presence of serial dilutions of the antiserum and in a parallel series of tubes containing in addition 50 pg of cold estradiol (Figure 3) . We chose as the working antiserum titer the dilution optimal 
Antiserum specificity.
Cross reactions of the antiserum to estriol-16,17-dihemisuccinate-BSA with the principal urinary steroids, measured according to Thorneycroft et al. (13) , are listed in Table 2 .
Effect of urine on the CL reaction. We selected 50 different urine specimens, containing various amounts of creatinine (0.5-3.1 g/L), uric acid (1.0-12.5 g/L), protein (0-10 g/L), and We evaluated the effect of urine on the efficiency of the CL reaction by measuring the light emitted by increasing amounts of the tracer (50-800 fmol/tube) in the presence of 0.5 pL of urine (urine sample); parallel control tubes (control sample) contained distilled water in place of urine (Table 3) .
COUNTS x iO
We calculated the regression equation between the measured counts and the amount of the tracer, both for urine and control tubes. The respective mean blank values were <o.oi Fig. 4 . Calibration curveforthe luminescence immunoassay for "total" estrogen Each point represents the mean ± SD of 10 differentexperiments subtracted from each count before the regression analysis (Table 3) .
Assay Characteristics
Sensitivity.
When we used 17/3-estradiol as the competitor, the minimum steroid concentration that could be distinguished from zero was calculated from 10 different calibration curves, prepared in triplicate (Figure 4) . The mean value we obtained was 2 pg per tube, which is equivalent to 4 g/L of urine.
Analytical recovery.
We added increasing amounts these two pooled samples were stored at -20 #{176}C and analyzed in 12 different assays during two months. The between-assay precision was then calculated (Table 4) .
Correlation with the Fluorometric Method
The concentration of "total" urinary estrogens as measured by the present method (y) and a conventional fluorometric method (x) (14) gave the linear regression equation y = 2.506x -2.823 (r = 0.958, n = 50).
Reference Intervals
The concentration of "total" estrogens in early-morning urine samples collected daily from 15 healthy women are shown in Figure 5 . The results are expressed in terms of creatinine. The creatimne was measured in an AutoAnalyzer (Technicon Instruments Corp., Tarrytown, NY) by a procedure based on the Jaff#{233} alkaline picrate reaction.
Discussion
This method allows direct measurement of "total" estrogen in urine by an homogeneous luminescent immunoassay of enzymically Many recent papers deal with the effect on the CL reaction of binding to a specific protein (15) (16) (17) , and they show different behavior according to the labeled steroidantibody complex being investigated. In our case, the binding of E2-ABEI to the estriol-16,17-dihemisuccinate-BSA antiserum resulted in a marked increase in the efficiency of the CL reaction, in terms of light emission, which allowed development of an homogeneous immunoassay.
A particular antiserum must be used when one is per- Table 4 . Precision Evaluation forming an immunoassay for a group of compounds instead of a conventional immunoassay for individual compounds: the antiserum should specifically recognize those compounds carrying a particular chemical group and it should cross react fully with them. Our antiserum showed a very good affinity towards estrogens and very low cross reaction with the other principal steroids in urine. Of the principal estrogens, estrone and 17/3-estradiol appeared to be bound with higher affinity than estriol. Because 17f3-estradiol was used as the reference compound, the method thus should underestimate estriol by about 40% and overestimate estrone by about 10%. Chemical methods for total estrogens have this same drawback; analytical recoveries differ for the individual steroids (6) .
The main problem in developing highly sensitive luminescent methods for use with crude biological samples probably arises from interference with the light-producing reaction. Some components of plasma and urine have already been reported to affect the CL reactions (17-19) . The urine samples we tested contained various amounts of the most widely reported interfering substances and showed a mean background emission twofold higher than the reagent blank. This interference was almost constant for the urmnes we tested (CV = 15%) and, moreover, it was negligible compared with the number of counts emitted by the tracer throughout the whole range of the reference curve (see Table 1 ).
No significant difference was found (Table 3 ) when we measured the light emission of the tracer alone or in the presence of 0.5 L of urine sample. The recovery test showed that the procedure as a whole was unaffected by the presence of 0.5 .tL of urine. Nevertheless, the CL reaction appeared to be markedly slower for the urine tubes than for the standard tubes, possibly because of a competitive influence of some component(s) of urine.
To allow the luminometer to record the light emission in all tubes under the same conditions and to correct for the slight background interference, we used as diluent for the standards a pooled specimen of urine from healthy infants younger than three years. The estrogen content of this pooled urine was <1 pg/L as measured by the fluorometric assay.
In terms of accuracy and precision, the method appears fully satisfactory and results are comparable with those by the most widely used radioimmunological ones. They also correlate well with the conventional fluorometric method, although the immunological values were more than twofold higher than the fluorometric ones.
Similar discrepancies between immunological
and chemical estrogen assays have been reported (6, 20) and were mainly attributed to procedural losses associated with the solvent extraction and the acid hydrolysis of the chemical methods.
The proposed method seems to overcome many drawbacks of the conventional estrogen-evaluation tests. The "total" estrogen value is related to the concentration of all the main urinary metabolites of 17/3-estradiol, and it can be considered representative of ovarian estrogen production. Moreover, efficient monitoring of ovarian function requires that the test be performed several times during the menstrual cycle. Measurement of estrogens in daily collections of the early-morning urine has already been proposed for this purpose in addition to assays for lutropmn and pregnandiol (21). The patient herself can store at home a small sample from this collection until the end of the cycle, with considerable psychological and practical advantages over blood drawing or 24-h urine collection. However, if many samples must be assayed, the adopted method must be easy, economical, and preferably should not involve polluting (radioac-tive) reagents. The present method involves a tracer that can be easily prepared in the clinical chemistry laboratory and which is then stable for a long time. Because this homogeneous method requires no bound/free separation step, it may be easily automated.
When a rapid (1 h) hydrolysis is used, the method should allow daily monitoring of ovulation, as required in the course of stimulation with urogonadotropin (Pergonal).
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